← Back to home

EBV+ POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN CENTRAL NERVOUS SYSTEM (EBV+ CNS PTLD)

Clinical trials for EBV+ POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN CENTRAL NERVOUS SYSTEM (EBV+ CNS PTLD) explained in plain language.

Never miss a new study

Get alerted when new EBV+ POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN CENTRAL NERVOUS SYSTEM (EBV+ CNS PTLD) trials appear

Sign up with your email to follow new studies for EBV+ POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN CENTRAL NERVOUS SYSTEM (EBV+ CNS PTLD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

Experimental cell therapy targets Virus-Driven cancers in vulnerable patients

Disease control Recruiting now

This study is testing an experimental cell therapy called tabelecleucel for cancers and tumors caused by the Epstein-Barr virus (EBV) in people with weakened immune systems. The treatment involves giving patients specially prepared immune cells designed to fight EBV-infected cell…

Matched conditions: EBV+ POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN CENTRAL NERVOUS SYSTEM (EBV+ CNS PTLD)

Phase: PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control

Last updated Apr 04, 2026 06:51 UTC

EBV+ POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN CENTRAL NERVOUS SYSTEM (EBV+ CNS PTLD)

Get alerted when new EBV+ POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN CENTRAL NERVOUS SYSTEM (EBV+ CNS PTLD) trials appear

Experimental cell therapy targets Virus-Driven cancers in vulnerable patients